Physician profile
Yue Ding
NPI 1104213834
$297.01
in general payments reported to CMS, 2019-2025
12 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $47.61 · 2021: $121 · 2023: $86.04 · 2024: $42.33.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $128.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $128.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $41.94 | 2021-2024 | |
| Actelion Pharmaceuticals US, INC. | $39.97 | 2023 | Uptravi, Opsumit |
| Amgen INC. | $26.48 | 2023 | Prolia, Evenity |
| United Therapeutics Corporation | $24.64 | 2020 | |
| Mallinckrodt Hospital Products INC. | $24.37 | 2021 | |
| Horizon Therapeutics Plc | $23.30 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $22.97 | 2020 | |
| Glaxosmithkline, LLC. | $21.85 | 2024 | Benlysta |
| Octapharma USA, INC. | $19.59 | 2023 | Octagam Immune Globulin (Human) |
| Ucb, INC. | $19.30 | 2021 | |
| Abbvie INC. | $18.78 | 2021 | |
| Gilead Sciences, INC. | $13.82 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Yue Ding listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.